ClinicalTrials.gg
Status unknownNCT04570345BULK-STEMIUpdated Dec 22, 2020

3 Months Versus 12 Months Dual Antiplatelet Therapy After Drug-eluting Stent Implantation in STEMI

A Phase 4 interventional study of ticagrelor monotherapy and Aspirin with P2Y12 receptor inhibitor in ST Elevation Myocardial Infarction, sponsored by Dong-A University. Status unknown at 1 site in Korea, Republic of. Open to participants aged 19 Years to 79 Years. Per ClinicalTrials.gov, last updated 2020-12-22.

Sponsored by Dong-A University · Phase 4, Interventional, and Treatment

How we know

The sponsor has not verified this record recently (last verified Dec 2020), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
1,002
Allocation
Randomized
Ages
19 Years to 79 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 36 studies in ST Elevation Myocardial Infarction with a site in Korea, Republic of — 8 open to participants now, 12 under way, 2 of them phase 3. ST Elevation Myocardial Infarction · Korea, Republic of.

Planned enrollment
8th of 28
1,002 · median 314
Started
2021
with 1 other
Phase 4
6 of 36
1 open now
Registered
25th of 36
by date
Lead sponsor
2 of 36
Dong-A University

Among the 36 studies in ST Elevation Myocardial Infarction with a site in Korea, Republic of, this one is the 8th largest by planned enrollment of the 28 interventional ones that give a count, is one of 2 that started in 2021, is one of 6 in phase 4, and was the 25th registered.

ST Elevation Myocardial Infarction

855 studies on the registry are indexed under ST Elevation Myocardial Infarction; 201 are open to participants now.

Browse ST Elevation Myocardial Infarction studies →

Open to participants now

8 of the 36 studies in ST Elevation Myocardial Infarction with a site in Korea, Republic of are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 124 ST Elevation Myocardial Infarction studies recruiting now, 78 (63%) set no upper age limit and 20 (16%) stop at 75 or younger; 10 take children under 18; 9 take healthy volunteers.

This study: 19 Years to 79 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies in ST Elevation Myocardial Infarction with a site in Korea, Republic of, or all of them as a file.
02

Study summary

To compare the clinical outcomes of dual antiplatelet therapy with aspirin and P2Y12 receptor inhibitor vs. ticagrelor monotherapy at 3 months after PCI in patients with ST-elevation myocardial infarction.

Read the detailed description

The purpose of this study is to compare the use of ticagrelor alone versus P2Y12 receptor inhibitor and aspirin together after PCI among ST-elevation myocardial infarction patients who complete 3-month course of dual antiplatelet therapy. The object of this study is to determine the effectiveness and safety of ticagrelor alone, compared to P2Y12 receptor inhibitor plus aspirin in reducing clinically relevant bleeding and in reducing ischemic adverse events among patients diagnosed with ST-elevation myocardial infarction undergoing PCI with second-generation drug-eluting stent.

03

Conditions studied

  • ST Elevation Myocardial Infarction
04

Who can participate

Ages eligible
19 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients ≥ 19 years old
  • Patients who received new generation sirolimus-eluting (Osiro®) stent implantation for treating ACS
  • Provision of

Exclusion criteria

Exclusion Criteria:

  • Age > 80 years
  • Pregnant women or women with potential childbearing
  • \< 1 year
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,002 participants (estimated)

Study arms

  • Experimental
    Ticagrelor monotherapy

    Ticagrelor monotherapy after 3-month DAPT(aspirin with ticagrelor)

    Drug: ticagrelor monotherapy

  • Active comparator
    Aspirin with P2Y12 receptor inhibitor

    Aspirin with P2Y12 receptor inhibitor after 3-month DAPT(aspirin with ticagrelor)

    Drug: ticagrelor monotherapy · Drug: Aspirin with P2Y12 receptor inhibitor

Interventions

  • DrugTicagrelorStudies of TicagrelorTicagrelor pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    • Drug: ticagrelor monothearpy after first 3 months dual therapy

    Also known as: Study group

  • DrugAspirin with P2Y12 receptor inhibitor

    • Drug: aspirin plus ticagrelor dual therapy during 12 months

    Also known as: Control group

06

What researchers measure

Primary outcomes

  1. NACE: net clinical adverse event

    The sum of major adverse cardiac and cerebrovaascular event(MACCE) and bleeding event(BARC score)

    Time frame: 12 months after randomization

  2. Major adverse cardiac and cerebrovaascular event(MACCE)

    Major adverse cardiac and cerebrovaascular event(MACCE) includes 1)all-cause motality, 2) acute MI, 3)cerebrovascular event, 4)stent thrombosis

    Time frame: 12 months after randomization

  3. Major bleeding (BARC type 3,5)

    The number of participants with first occurrence of clinically relevant bleeding episode, defined as Bleeding Academic Research Consortium (BARC) Types 3 or 5 bleeding. BARC bleeding types range from 0 (no bleeding) to 5 (fatal bleeding). type 3a: Overt bleeding plus hemoglobin drop of 3 to \< 5 g/dL (provided hemoglobin drop is related to bleed); transfusion with overt bleeding, type 3b: Overt bleeding plus hemoglobin drop \< 5 g/dL (provided hemoglobin drop is related to bleed); cardiac tamponade; bleeding requiring surgical intervention for control; bleeding requiring IV vasoactive agents, type 3c: Intracranial hemorrhage confirmed by autopsy, imaging, or lumbar puncture; intraocular bleed compromising vision, type 5a: Probable fatal bleeding, type 5b: Definite fatal bleeding (overt or autopsy or imaging confirmation in accordance with BARC Definitions

    Time frame: 12 months after randomization

Secondary outcomes

  1. Individual component of MACCE and bleeding episode

    1. All-cause mortality :Individual component of MACCE 2. Acute MI :Individual component of MACCE 3. Cerebrovascular event :Individual component of MACCE 4. Stent thrombosis :Definite or probable stent thrombosis defined by Academic Research Consortium (ARC) 5. Bleeding :Bleeding Academic Research Consortium (BARC) type 3 or 5

    Time frame: 12 months after randomization

07

Study locations

1 of 1 sites recruiting
  • Department of Internal Medicine,Dong-A University College of Medicine
    Busan, Korea, Republic of
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2021; primary completion for Aug 2021, 7 months later.

Of 44 non-industry phase 4 interventional studies under ST Elevation Myocardial Infarction, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 74. This study's planned 7 months is below that.

Counting every sponsor, half of 49 studies reached it within 34 months; a quarter within 22 and three quarters within 63.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 25, 2020
First posted
Sep 30, 2020
StartEst.
Jan 1, 2021
Primary completionEst.
Aug 31, 2021
CompletionEst.
Aug 2022
Last update
Dec 22, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 22, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04570345
Lead sponsor
Dong-A University
Responsible party
Kyungil Park (Associate professor, Dong-A University) — Principal investigator
First posted
Sep 30, 2020
Start date
Jan 1, 2021 (estimated)
Primary completion
Aug 31, 2021 (estimated)
Completion
Aug 2022 (estimated)
Last update
Dec 22, 2020

Study contacts

Kyungil Park, Ph.D
Contact
cardiopark@gmail.com
82-51-240-2733
Kyungil Park, Ph.D
principal investigator · Dong-A University Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion